 SOUTH SAN FRANCISCO, Calif., April 15, 2021 PRNewswire -- IDEAYA Biosciences, Inc. NASDAQ: IDYA, a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced First-Patient-In FPI in the Phase 1 clinical trial evaluating IDE397 ClinicalTrials.gov Identifier: NCT04794699. 